The Medical Letter - 2017
Search or Select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
January 2, 2017 (Issue 1511)
- Antiviral Drugs for Seasonal Influenza 2016-2017
Superseded by The Medical Letter "Antiviral Drugs for Influenza for 2020-2021" - Issue 1610, November 2, 2020Antiviral drugs can be used for prophylaxis and treatment of influenza.... - Another Insulin Glargine (Basaglar) for Diabetes
The FDA has approved Basaglar (Lilly/Boehringer Ingelheim), a "follow-on" 100 units/mL insulin glargine product similar to Lantus (Sanofi), which recently went off patent. A 300... - Ustekinumab (Stelara) for Crohn's Disease
The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab (Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who... - Tenofovir Alafenamide (Vemlidy) for Hepatitis B
The FDA has approved tenofovir alafenamide (Vemlidy – Gilead) for treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. It is the first...
January 16, 2017 (Issue 1512)
- Drugs for Type 2 Diabetes
Superseded by The Medical Letter "Drugs for Type 2 Diabetes" - Issue 1584, November 4, 2019The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal...
January 30, 2017 (Issue 1513)
- Lixisenatide for Type 2 Diabetes
The FDA has approved lixisenatide (Sanofi), a short-acting injectable GLP-1 (glucagon-like peptide-1) receptor agonist, for once-daily treatment of adults with type 2 diabetes, both alone... - Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC
The FDA has approved the immune checkpoint inhibitor pembrolizumab (Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, for first-line treatment of patients with... - Inflectra - An Infliximab Biosimilar
The FDA has approved infliximab-dyyb (Inflectra – Pfizer; marketed as Remsima in some countries), as a biosimilar of the TNF inhibitor infliximab... - Yosprala - A Combination of Aspirin and Omeprazole
The FDA has approved Yosprala (Aralez), a fixed-dose combination of delayed-release aspirin and immediate-release omeprazole, for secondary prevention of cardiovascular and... - Drug Interaction: Dabigatran (Pradaxa) and Statins
The results of a recently published study suggest that taking the oral direct thrombin inhibitor dabigatran etexilate (Pradaxa) with either simvastatin (Zocor, and others) or... - Corrections: Drugs for Diabetes & Another Insulin Glargine (Basaglar) for Diabetes
Drugs for Diabetes (Med Lett Drugs Ther 2017; 59:9)In the 4th paragraph of the GLP-1 receptor agonists section, we mistakenly stated that Xultophy 100/3.6 is a combination... - Comparison Table: SGLT2 Inhibitors (online only)
Superseded by The Medical Letter "Comparison Chart: SGLT2 Inhibitors (online only)" - Issue 1611, November 16, 2020View the Comparison Table: SGLT2 Inhibitors
February 13, 2017 (Issue 1514)
- Drugs for Migraine
Superseded by The Medical Letter "Drugs for Migraine" - Issue 1608, October 5, 2020An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without... - Comparison Table: Triptans for Migraine (online only)
View the Comparison Table: Triptans for Migraine - Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
February 27, 2017 (Issue 1515)
- Auvi-Q Epinephrine Auto-Injector Returns
Auvi-Q (Kaléo; previously manufactured and marketed by Sanofi), the epinephrine auto-injector approved by the FDA in 2012 for emergency treatment of anaphylaxis and voluntarily withdrawn... - Crisaborole (Eucrisa) for Atopic Dermatitis
The FDA has approved crisaborole 2% ointment (Eucrisa – Pfizer) for topical treatment of mild to moderate atopic dermatitis in patients ≥2 years old. It is the first phosphodiesterase... - Anticoagulation of Elderly Patients at High Risk for Falls with Atrial Fibrillation
With the widespread adoption of the CHA2DS2-VASc scoring system, oral anticoagulation therapy is now recommended for all patients ≥75 years old with nonvalvular atrial... - Extended-Release Calcifediol (Rayaldee) for Secondary Hyperparathyroidism
The FDA has approved extended-release (ER) calcifediol (25-hydroxyvitamin D3; Rayaldee – Opko), a prohormone of calcitriol, the active form of vitamin D3. It is indicated for treatment... - Kyleena - Another Hormonal IUD
The FDA has approved Kyleena (Bayer), an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy. It is the fourth... - Drug Interaction: Clopidogrel and PPIs
The antiplatelet drug clopidogrel (Plavix, and others) reduces major cardiovascular events, but can cause bleeding. Proton pump inhibitors (PPIs) are often used with clopidogrel to prevent... - Atezolizumab (Tecentriq) for Bladder Cancer and NSCLC (online only)
The FDA has approved the immune checkpoint inhibitor atezolizumab (Tecentriq – Genentech) for treatment of locally advanced or metastatic urothelial carcinoma and metastatic non-small...
March 13, 2017 (Issue 1516)
- Drugs for Hypertension
Superseded by The Medical Letter "Drugs for Hypertension" - Issue 1598, May 18, 2020in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of...
March 27, 2017 (Issue 1517)
- Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium difficile Infection
The FDA has approved the fully human monoclonal antibody bezlotoxumab (Zinplava – Merck) for use with antibacterial drug treatment to reduce recurrence of Clostridium difficile... - Nusinersen (Spinraza) for Spinal Muscular Atrophy
The FDA has approved nusinersen (Spinraza – Biogen) for treatment of spinal muscular atrophy (SMA), a hereditary neurodegenerative disease that occurs in about one in every 10,000... - Exablate Neuro for Essential Tremor
The FDA has approved use of Exablate Neuro (Insightec) for unilateral thalamotomy to treat medication-refractory essential tremor in patients ≥22 years old. Exablate Neuro uses... - Obeticholic Acid (Ocaliva) for Primary Biliary Cholangitis
Obeticholic acid (Ocaliva – Intercept), a farnesoid X receptor agonist, has been approved by the FDA for treatment of primary biliary cholangitis; it is indicated for use in combination... - Triferic for Iron Replacement
The FDA has approved ferric pyrophosphate citrate solution (Triferic – Rockwell Medical) to maintain hemoglobin concentrations in adults with hemodialysis-dependent chronic kidney... - Inhibitors and Inducers of CYP Enzymes and P-Glycoprotein (online only)
Superseded by The Medical Letter "Inhibitors and Inducers of CYP Enzymes and P-Glycoprotein (online only)" - Issue 1607, September 21, 2020View the Inhibitors and Inducers of CYP Enzymes and...
April 10, 2017 (Issue 1518)
- Drugs for COPD
Superseded by The Medical Letter "Drugs for COPD" - Issue 1606, September 7, 2020The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce... - Comparison Table: Inhaled Short-Acting Bronchodilators for COPD (online only)
Superseded by The Medical Letter "Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD (online only)" - Issue 1606, September 7, 2020View the Comparison Table:... - Comparison Table: Inhaled Long-Acting Bronchodilators for COPD (online only)
Superseded by The Medical Letter "Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD (online only)" - Issue 1606, September 7, 2020View the Comparison Table: Inhaled... - Comparison Table: Some Inhaled Corticosteroids for COPD (online only)
Superseded by The Medical Letter "Comparison Table: Inhaled Corticosteroids for Treatment of COPD (online only)" - Issue 1606, September 7, 2020View the Comparison Table: Some Inhaled... - Table: Correct Use of Inhalers for COPD (online only)
Superseded by The Medical Letter "Table: Correct Use of Inhalers for COPD (online only)" - Issue 1606, September 7, 2020View the Table: Correct Use of Inhalers for COPD
April 24, 2017 (Issue 1519)
- Reduction of Cardiovascular Risk with Evolocumab (Repatha)
The results of the recently published FOURIER trial have shown a reduction in cardiovascular events with addition of the PCSK9 inhibitor evolocumab (Repatha) to statin therapy in patients... - Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
The FDA has approved dupilumab (Dupixent – Sanofi/Regeneron), a subcutaneously-injected fully human monoclonal antibody, for treatment of adults with moderate to severe atopic dermatitis... - Plecanatide (Trulance) for Chronic Idiopathic Constipation
The FDA has approved plecanatide (Trulance – Synergy), a guanylate cyclase-C receptor agonist, for treatment of chronic idiopathic constipation (CIC) in adults. Linaclotide... - Arymo ER - A New Abuse-Deterrent Morphine Formulation
The FDA has approved Arymo ER (Egalet), a new extended-release, abuse-deterrent tablet formulation of morphine sulfate, for management of pain severe enough to require daily,... - In Brief: New Adult Immunization Recommendations
The 2017 adult immunization schedule approved by the CDC's Advisory Committee on Immunization Practices (ACIP) includes some new or revised recommendations.1 The complete schedule is available on... - In Brief: Pancreatitis with Eluxadoline (Viberzi) in Patients without a Gallbladder
The FDA has warned that eluxadoline (Viberzi – Allergan), a mu-opioid receptor agonist and delta-opioid receptor antagonist approved in 2015 for treatment of irritable bowel syndrome with... - OTC Fluticasone Furoate Nasal Spray (Flonase Sensimist) for Allergic Rhinitis (online only)
The nasal spray formulation of the corticosteroid fluticasone furoate is now available over the counter (OTC) as Flonase Sensimist Allergy Relief (GSK) in the same strength as the...
May 8, 2017 (Issue 1520)
- Drugs for Allergic Disorders
Superseded by The Medical Letter "Drugs for Allergic Rhinitis and Allergic Conjunctivitis" - Issue 1622, April 19, 2021Allergic rhinitis can be classified as seasonal, perennial, or... - Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)
Superseded by The Medical Letter "Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)" - Issue 1622, April 19, 2021View the Comparison Table: Some Oral Drugs for Allergic... - Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)
Superseded by The Medical Letter "Comparison Table: Some Nasal Sprays for Allergic Rhinitis (online only)" - Issue 1622, April 19, 2021View the Comparison Table: Some Nasal Sprays for... - Comparison Table: Some Topical Corticosteroids (online only)
View the Comparison Table: Some Topical Corticosteroids
May 22, 2017 (Issue 1521)
- Prescription Drug Prices in the US
Per capita spending on prescription drugs in the US is higher than in other industrialized nations, including Canada. - Valbenazine (Ingrezza) for Tardive Dyskinesia
The FDA has approved valbenazine (Ingrezza – Neurocrine Biosciences), a vesicular monoamine transporter 2 (VMAT2) inhibitor, for treatment of tardive dyskinesia in adults. It is the... - Oxymetazoline Cream (Rhofade) for Rosacea
The FDA has approved the selective alpha1A-adrenergic receptor agonist oxymetazoline as a 1% cream (Rhofade – Allergan) for topical treatment of persistent facial erythema of... - FDA Warns Against Use of Codeine and Tramadol in Children and Breastfeeding Women
The FDA has issued new warnings about the use of the opioid analgesics codeine and tramadol in children, particularly those - Another Subcutaneous Immune Globulin (Cuvitru) for Primary Immunodeficiency (online only)
The FDA has approved a subcutaneously administered 20% solution of human immune globulin (Cuvitru – Shire) for replacement therapy in patients ≥2 years old with a primary humoral... - Vonvendi - Recombinant von Willebrand Factor (online only)
The FDA has approved intravenously administered recombinant von Willebrand factor (Vonvendi - Shire) for adults with von Willebrand disease (VWD) who require on-demand treatment and... - Comparison Table: Some Topical Drugs for Rosacea (online only)
View the Comparison Table: Some Topical Drugs for Rosacea
June 5, 2017 (Issue 1522)
- Drugs for Opioid Use Disorder
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of... - Abuse-Deterrent Opioids
Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Since our last article... - Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder (online only)
View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder
June 19, 2017 (Issue 1523)
- Abaloparatide (Tymlos) for Postmenopausal Osteoporosis
The FDA has approved abaloparatide (Tymlos – Radius Health), a synthetic analog of human parathyroid hormone related peptide, for treatment of postmenopausal women with osteoporosis... - Ocrelizumab (Ocrevus) for MS
The FDA has approved ocrelizumab (Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS).... - Acetylcysteine (Cetylev) for Acetaminophen Overdose
The FDA has approved an effervescent tablet formulation of acetylcysteine (Cetylev – Arbor) to prevent or lessen hepatic injury after acetaminophen overdose. Acetylcysteine has been... - Obalon Balloon System - Another Gastric Balloon for Weight Loss
The FDA has approved the Obalon Balloon System (Obalon), a swallowable intragastric gas-filled balloon device, to facilitate weight loss in adults with a body mass index (BMI) of 30-40... - Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus
The FDA has approved the ophthalmic solutions riboflavin 5'-phosphate in 20% dextran (Photrexa Viscous – Avedro) and riboflavin 5'-phosphate alone (Photrexa) for use with... - Comparison Table: Drugs for Postmenopausal Osteoporosis (online only)
Superseded by The Medical Letter "Comparison Table: Some Drugs for Postmenopausal Osteoporosis (online only)" - Issue 1602, July 13, 2020View the Comparison Table: Drugs for Postmenopausal...
July 3, 2017 (Issue 1524)
- Drugs for Sexually Transmitted Infections
The text and tables that follow include recommendations for management of sexually transmitted infections (STIs) other than HIV and viral hepatitis. Some of the indications and dosages...
July 17, 2017 (Issue 1525)
- Drugs for Helicobacter pylori Infection
About 50% of the world’s population is infected with Helicobacter pylori. These gastric bacteria can cause chronic inflammation and have been associated with development of gastritis,... - Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis
The FDA has approved brodalumab (Siliq – Valeant), an injectable human interleukin (IL)-17A receptor antagonist, for treatment of adults with moderate to severe plaque psoriasis who have... - Telotristat Ethyl (Xermelo) for Carcinoid Syndrome Diarrhea
The FDA has approved telotristat ethyl (Xermelo – Lexicon), a tryptophan hydroxylase inhibitor, for use in combination with a somatostatin analog (SSA) for treatment of carcinoid... - In Brief: Avelumab (Bavencio) for Metastatic Merkel Cell Carcinoma (online only)
The FDA has approved the fully-human programmed death ligand 1 (PD-L1) blocking antibody avelumab (Bavencio – EMD Serono/Pfizer) for treatment of metastatic Merkel cell carcinoma (MCC) in...
July 31, 2017 (Issue 1526)
- Drugs for Epilepsy
Treatment of epilepsy should begin with a single antiepileptic drug (AED), increasing its dosage gradually until seizures are controlled or adverse effects become intolerable. If seizures... - Comparison Table: Some Oral Antiepileptic Drugs (online only)
View the Comparison Table: Some Oral Antiepileptic Drugs
August 14, 2017 (Issue 1527)
- Safety of Long-Term PPI Use
Proton pump inhibitors (PPIs), which are used for treatment of gastroesophageal reflux disease (GERD) and for prevention of upper gastrointestinal adverse effects caused by NSAIDs and aspirin,... - Sarilumab (Kevzara) for Rheumatoid Arthritis
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab (Kevzara – Sanofi) for second-line treatment of adults with moderately to severely active rheumatoid arthritis (RA). It is... - Cardiovascular Effects of Some Antidiabetic Drugs
For many years, the goal of drug therapy for most patients with type 2 diabetes has been to achieve and maintain an A1C of - Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only)
Olaratumab (Lartruvo – Lilly), a platelet-derived growth factor receptor alpha (PDGFR-α) blocking monoclonal antibody, has received accelerated approval from the FDA for use in combination... - In Brief: Midostaurin (Rydapt) for AML and Advanced Systemic Mastocytosis (online only)
The FDA has approved the oral multikinase inhibitor midostaurin (Rydapt – Novartis) for first-line treatment, in addition to standard chemotherapy, of adults with FLT3 (fms-like tyrosine...
August 28, 2017 (Issue 1528)
- Drugs for Asthma
Superseded by The Medical Letter "Drugs for Asthma" - Issue 1613, December 14, 2020The goal of asthma treatment is to control symptoms and prevent exacerbations. Management of... - Comparison Table: Some Inhaled Drugs for Treatment of Asthma (online only)
Superseded by The Medical Letter "Some Inhaled Drugs for Treatment of Asthma (online only)" - Issue 1613, December 14, 2020View the Comparison Table: Some Inhaled Drugs for Treatment of Asthma - Comparison Table: Correct Use of Inhalers for Asthma (online only)
Superseded by The Medical Letter "Correct Use of Inhalers for Asthma (online only)" - Issue 1613, December 14, 2020View the Comparison Table: Correct Use of Inhalers
September 11, 2017 (Issue 1529)
- Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
The FDA has approved Xultophy 100/3.6 (Novo Nordisk), a fixed-ratio combination of insulin degludec and the GLP-1 (glucagon-like peptide-1) receptor agonist liraglutide, for once-daily... - Prasterone (Intrarosa) for Dyspareunia
The FDA has approved the steroid prasterone (Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy... - Safinamide (Xadago) for Parkinson's Disease
The FDA has approved the monoamine oxidase type B (MAO-B) inhibitor safinamide (Xadago – US Worldmeds) as an adjunct to levodopa/carbidopa for management of "off" episodes in patients... - Deflazacort (Emflaza) for Duchenne Muscular Dystrophy
Deflazacort (Emflaza – PTC Therapeutics), an oral corticosteroid, has been approved by the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients ≥5 years old. It has been... - Correction: Drugs for Helicobacter pylori Infection
In Table 3 on page 116 (Med Lett Drugs Ther 2017; 59:113), the price provided for Prevpac was for a 14-day supply, rather than for a 10-day supply as stated in footnote 1. The footnote has...
September 25, 2017 (Issue 1530)
- Drugs for Cognitive Loss and Dementia
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies,... - Tocilizumab (Actemra) for Giant Cell Arteritis
The FDA has approved the interleukin-6 (IL-6) receptor antagonist tocilizumab (Actemra – Genentech) for subcutaneous (SC) treatment of giant cell arteritis in adults. It is the first... - Comparison Table: Drugs for Alzheimer's Disease (online only)
View the Comparison Table: Drugs for Alzheimer's Disease
October 9, 2017 (Issue 1531)
- Influenza Vaccine for 2017-2018
Superseded by The Medical Letter "Influenza Vaccine for 2020-2021" - Issue 1607, September 21, 2020Routine annual vaccination against influenza A and B viruses is recommended for everyone... - Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection
The FDA has approved Mavyret (Abbvie) and Vosevi (Gilead), two new fixed-dose combinations of direct-acting antiviral (DAA) drugs, for treatment of chronic hepatitis C virus (HCV)... - In Brief: Pancreatic Enzyme Replacement Products
Pancreatic enzyme replacement products have been used for years to improve digestion in patients with exocrine pancreatic insufficiency (EPI). These products were initially marketed before formal...
October 23, 2017 (Issue 1532)
- Drugs for Common Bacterial Infections in Adults
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and... - Tisagenlecleucel (Kymriah) for ALL
The FDA has approved tisagenlecleucel (Kymriah — Novartis), an individualized, genetically-modified cellular product, for treatment of relapsed or refractory B-cell precursor acute... - Correction: Drugs for Cognitive Loss and Dementia
In our article on Drugs for Cognitive Loss and Dementia (Med Lett Drugs Ther 2017; 59:155), the last sentence at the end of the article should have been omitted. It has been deleted from the... - Ribociclib (Kisqali) for Advanced or Metastatic Breast Cancer (online only)
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (Kisqali – Novartis) has been approved by the FDA for use in combination with an aromatase inhibitor for first-line...
November 6, 2017 (Issue 1533)
- Guselkumab (Tremfya) for Psoriasis
The FDA has approved the interleukin (IL)-23 blocker guselkumab (Tremfya – Janssen) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy... - Edaravone (Radicava) for ALS
The FDA has approved edaravone (Radicava – Mitsubishi Tanabe Pharma) for treatment of amyotrophic lateral sclerosis (ALS). It is the second drug to be approved in the US for this... - Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia
The FDA has approved Duzallo (Ironwood), a fixed-dose combination of the uric acid transporter 1 (URAT1) inhibitor lesinurad (Zurampic) and the xanthine oxidase inhibitor... - Cotempla XR-ODT - Another Long-Acting Methylphenidate for ADHD
The FDA has approved an extended-release orally disintegrating tablet formulation of methylphenidate (Cotempla XR-ODT – Neos Therapeutics) for once-daily treatment of attention-defi... - Abemaciclib (Verzenio) - A Third CDK 4/6 Inhibitor for Breast Cancer
The FDA has approved abemaciclib (Verzenio – Lilly), an oral cyclin-dependent kinase (CDK) 4/6 inhibitor, for treatment of hormone receptor (HR)-positive, human epidermal growth factor...
November 20, 2017 (Issue 1534)
- Drugs for Parkinson's Disease
Superseded by The Medical Letter "Drugs for Parkinson's Disease" - Issue 1618, February 22, 2021The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of... - Comparison Table: Drugs for Parkinson's Disease (online only)
Superseded by The Medical Letter "Comparison Table: Drugs for Parkinson's Disease (online only)" - Issue 1618, February 22, 2021View the Comparison Table: Drugs for Parkinson's Disease
December 4, 2017 (Issue 1535)
- Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine
The FDA has approved an adjuvanted, recombinant varicella zoster virus (VZV) vaccine (Shingrix – GSK) for prevention of herpes zoster (shingles) in adults ≥50 years old.... - Naldemedine (Symproic) for Opioid-Induced Constipation
The FDA has approved the opioid receptor antagonist naldemedine (Symproic – Shionogi) for treatment of opioid-induced constipation (OIC) in adults with chronic noncancer pain.... - Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease
The FDA has approved an extended-release (ER) capsule formulation of amantadine (Gocovri – Adamas) for once-daily treatment of levodopa-induced dyskinesia in patients with... - PARP Inhibitors for Ovarian Cancer
Three oral poly(ADP-ribose) polymerase (PARP) inhibitors have been approved by the FDA for treatment of advanced, recurrent ovarian cancer. Olaparib (Lynparza – AstraZeneca), niraparib... - In Brief: New Hypertension Guidelines
Superseded by The Medical Letter "Drugs for Hypertension" - Issue 1598, May 18, 2020New US guidelines for the treatment of hypertension have recently been published.1Probably the most... - Three More Immune Checkpoint Inhibitors for Advanced Bladder Cancer (online only)
The FDA has approved avelumab (Bavencio – EMD Serono) and durvalumab (Imfinzi – AstraZeneca), two new immune check point inhibitors, and pembrolizumab (Keytruda –...
December 18, 2017 (Issue 1536)
- Drugs for Postmenopausal Osteoporosis
Superseded by The Medical Letter "Drugs for Postmenopausal Osteoporosis" - Issue 1602, July 13, 2020Diagnosis of osteoporosis is based on the results of bone mineral density (BMD) testing or... - Comparison Table: Some Drugs for Postmenopausal Osteoporosis (online only)
Superseded by The Medical Letter "Comparison Table: Some Drugs for Postmenopausal Osteoporosis (online only)" - Issue 1602, July 13, 2020View the Comparison Table: Drugs for Postmenopausal... - 2017 Annual Index (Online Only)
View the 2017 Annual Index